ArticleAmerican journal of translational research2025
Oral paroxetine improves symptoms and quality of life in refractory irritable bowel syndrome: a retrospective study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of oral paroxetine in improving symptoms and quality of life in patients with refractory irritable bowel syndrome (IBS).
methodsClinical data of 80 refractory IBS patients treated at Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences from January to December 2023 were retrospectively analyzed. The control group (n = 40) received prokinetic agents/pinaverium bromide plus lifestyle and dietary modifications, supplemented with antispasmodics and intestinal flora regulation. The paroxetine group (n = 40) received additional paroxetine hydrochloride (20 mg, once daily). Outcomes were assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), Bristol Stool Form Scale (BSFS), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), and IBS Quality of Life (IBS-QoL) before and after intervention. Adverse effects were recorded. Pearson correlation was used to examine associations between IBS-SSS and baseline variables, and logistic regression was applied to identify predictors of post-intervention quality of life.
resultsBoth groups improved across IBS-SSS, BSFS, SAS, SDS, and IBS-QoL after treatment, but improvements were significantly greater in the paroxetine group, particularly at 12 weeks (all P < 0.05). Age (t = 3.794, P = 0.002) and gender (F = 4.312, P = 0.001) independently influenced quality of life. Correlation analysis showed that IBS-SSS scores at week 12 were associated with age (R = -0.335), height (R = -0.389), and marital status (R = 0.134; all P < 0.05).
conclusionOral paroxetine provides significant and sustained relief of symptoms and improves quality of life in refractory IBS patients, with good safety for at least 12 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.